ClinicalTrials.gg
WithdrawnNCT03300401Updated May 16, 2019

Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization

An interventional study of Perflutren Lipid Microspheres and Sulfur Hexafluoride Lipid Microspheres in Hepatocellular Carcinoma, sponsored by University of Southern California. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-16.

Sponsored by University of Southern California · Not applicable, Interventional, and Diagnostic

Why this study was withdrawn
Accrual issue

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 926 studies in Carcinoma, Hepatocellular with a site in United States — 160 open to participants now, 245 under way, 17 of them phase 3. Carcinoma, Hepatocellular · United States.

Enrollment
737th of 775
0 · median 36
Started
2017
with 46 others
No phase
124 of 926
26 open now
Registered
523rd of 926
by date

Among the 926 studies in Carcinoma, Hepatocellular with a site in United States, this one is the 737th largest by enrollment of the 775 interventional ones that give a count, is one of 47 that started in 2017, is one of 124 with no phase, and was the 523rd registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

160 of the 926 studies in Carcinoma, Hepatocellular with a site in United States are open now. Recruiting first, the newest first:

155 more — sign in →

All 160 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 926 studies in Carcinoma, Hepatocellular with a site in United States, or all of them as a file.
02

Study summary

This pilot clinical trial studies how well contrast-enhanced ultrasound in diagnosing patients with liver cancer who are undergoing Yttrium-90 radioembolization. Contrast-enhanced ultrasound may provide detailed imaging of the tumor arteries after the injection of a contrast-agent consisting of microbubbles, and may predict how much Yttrium-90 will deposit in the tumor.

Read the detailed description

PRIMARY OBJECTIVES:

I. Investigate the relationship between hepatocellular carcinoma (HCC) tumor perfusion on pre-procedural contrast-enhanced ultrasound (CEUS) time intensity curve (TIC) and post-procedural Yttrium-90 (90Y) microsphere distribution after 90Y radioembolization (RE).

SECONDARY OBJECTIVES:

I. Study the potential of serial CEUS TIC examinations as a marker of tumor treatment response as assessed at 20 - 24 week computed tomography (CT) follow-up.

OUTLINE:

Patients receive perflutren or sulfur hexafluoride lipid microspheres and undergo CEUS at baseline, 2 and 4 weeks, and 3 and 6 months. Patients also undergo positron emission tomography/computed tomography (PET/CT) after standard of care 90Y radioembolization at baseline.

03

Conditions studied

  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients scheduled for 90Y radioembolization for HCC as part of their standard of care

Exclusion criteria

Exclusion Criteria:

  • Patients who have already received tumor treatment (either systemic or loco-regional such as previous Y90RE, microwave or radiofrequency [RF] ablation or transarterial chemoembolization [TACE])
  • Pregnant or nursing
  • Known cardiac shunt
  • Known pulmonary hypertension
  • History of to Definity (perflutren lipid microsphere) or Lumason
  • History of hypersensitivity to iodinated contrast agent
  • Cannot consent for himself or herself
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Diagnostic (CEUS)

    Patients receive perflutren or sulfur hexafluoride lipid microspheres and undergo CEUS at baseline, 2 and 4 weeks, and 3 and 6 months. Patients also undergo PET/CT after standard of care 90Y radioembolization at baseline.

    Drug: Perflutren Lipid Microspheres · Drug: Sulfur Hexafluoride Lipid Microspheres · Device: Dynamic Contrast-Enhanced Ultrasound Imaging · Device: Positron Emission Tomography · Device: Computed Tomography · Biological: Yttrium-90 (90Y)

Interventions

  • Receive intravenous injection just prior to ultrasound

    Also known as: Definity

  • Receive intravenous injection just prior to ultrasound

    Also known as: Lumason

  • DeviceDynamic Contrast-Enhanced Ultrasound Imaging

    Undergo Contrast-Enhanced Ultrasound Imaging

    Also known as: Contrast-Enhanced Ultrasound Imaging

  • DevicePositron Emission Tomography

    Undergo PET/CT

  • DeviceComputed Tomography

    Undergo CT scan

    Also known as: Computerized Axial Tomography

  • Given IV

    Also known as: 90Y microsphere

06

What researchers measure

Primary outcomes

  1. Local tumor response to therapy

    Will be assessed by modified Response Evaluation Criteria in Solid Tumors criteria.

    Time frame: Up to 24 weeks

07

Study locations

1 site
  • USC/Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2017 (actual). Primary completion is estimated for Nov 2019, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2017
First posted
Oct 3, 2017
StartActual
Nov 7, 2017
Primary completionEst.
Nov 7, 2019
CompletionEst.
Nov 7, 2020
Last update
May 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03300401
Responsible party
Sponsor
First posted
Oct 3, 2017
Start date
Nov 7, 2017
Primary completion
Nov 7, 2019 (estimated)
Completion
Nov 7, 2020 (estimated)
Last update
May 16, 2019

Study contacts

Harshawn Malhi, MD
principal investigator · University of Southern California

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Yttrium-90

Start the discussion